Matthijs S Ruiter
Overview
Explore the profile of Matthijs S Ruiter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zomer B, Ruiter M, Dekker F, Goertz E, de Haan M, Hemmelder M, et al.
J Vasc Access
. 2024 Jan;
25(6):2007-2017.
PMID: 38166508
Introduction: It is assumed that identification and correction of asymptomatic stenoses in the vascular access circuit will prevent thrombosis that would require urgent intervention to continue hemodialysis treatment. However, the...
2.
Maselli D, Garoffolo G, Cassanmagnago G, Vono R, Ruiter M, Thomas A, et al.
Front Cardiovasc Med
. 2022 Jun;
9:884031.
PMID: 35711359
Intimal hyperplasia is the leading cause of graft failure in aortocoronary bypass grafts performed using human saphenous vein (SV). The long-term consequences of the altered pulsatile stress on the cells...
3.
Garoffolo G, Ruiter M, Piola M, Brioschi M, Thomas A, Agrifoglio M, et al.
Theranostics
. 2020 Mar;
10(6):2597-2611.
PMID: 32194822
: Despite the preferred application of arterial conduits, the greater saphenous vein (SV) remains indispensable for coronary bypass grafting (CABG), especially in multi-vessel coronary artery disease (CAD). The objective of...
4.
Kenagy R, Kikuchi S, Evanko S, Ruiter M, Piola M, Longchamp A, et al.
PLoS One
. 2018 Sep;
13(9):e0204045.
PMID: 30265729
Changes in extracellular matrix proteins may contribute significantly to the adaptation of vein grafts to the arterial circulation. We examined the production and distribution of versican and hyaluronan in intact...
5.
Ruiter M, Doornbos A, de Waard V, de Winter R, Attevelt N, Steendam R, et al.
J Negat Results Biomed
. 2016 Dec;
15(1):20.
PMID: 27916002
Background: Drug-eluting stents (DES) have dramatically reduced restenosis rates compared to bare metal stents and are widely used in coronary artery angioplasty. The anti-proliferative nature of the drugs reduces smooth...
6.
Ruiter M, van Tiel C, Doornbos A, Marinkovic G, Strang A, Attevelt N, et al.
PLoS One
. 2015 Sep;
10(9):e0138459.
PMID: 26389595
Background: The introduction of drug-eluting stents (DES) has dramatically reduced restenosis rates compared with bare metal stents, but in-stent thrombosis remains a safety concern, necessitating prolonged dual anti-platelet therapy. The...
7.
Marinkovic G, Kroon J, Hoogenboezem M, Hoeben K, Ruiter M, Kurakula K, et al.
J Immunol
. 2014 Mar;
192(9):4370-8.
PMID: 24670805
Azathioprine and its metabolite 6-mercaptopurine (6-MP) are well established immunosuppressive drugs. Common understanding of their immunosuppressive properties is largely limited to immune cells. However, in this study, the mechanism underlying...
8.
Ruiter M, van Golde J, Schaper N, Stehouwer C, Huijberts M
Clin Sci (Lond)
. 2010 Jun;
119(6):225-38.
PMID: 20545627
Patients suffering from both diabetes and PAD (peripheral arterial disease) are at risk of developing critical limb ischaemia and ulceration, and potentially requiring limb amputation. In addition, diabetes complicates surgical...
9.
van Golde J, Ruiter M, Schaper N, Voo S, Waltenberger J, Backes W, et al.
Diabetes
. 2008 Jul;
57(10):2818-23.
PMID: 18633114
Objective: In this study, the effect of chronic hyperglycemia on acute ligation-induced collateral vasodilation, on monocyte chemotaxis, and on structural outward remodeling of collaterals was investigated. Research Design And Methods:...